Correlation between serum interleukin level, EBV-DNA titer and immunotherapeutic efficacy of nasopharyngeal carcinoma

Correlation between serum interleukin level, EBV-DNA titer and immunotherapeutic efficacy and quality of life of recurrent and metastatic nasopharyngeal carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052686

Enrollment

Unknown

Registered

2021-11-03

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Case series:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Sign the written informed consent; 2. The age at the time of enrollment is >= 18 years old; 3. Patients with recurrent and metastatic nasopharyngeal carcinoma diagnosed by pathology; 4. Receiving PD-1 inhibitor therapy; 5. If there are measurable lesions, evaluate the efficacy; 6. The patient has good compliance, and the subject must be willing to complete all visit evaluations at the research center according to the requirements of the trial protocol.

Exclusion criteria

Exclusion criteria: 1. Patients with acute infectious diseases; 2. Patients requiring long-term use of glucocorticoids; 3. Patients with a second primary tumor; 4. Patients who have received solid organ transplantation or bone marrow transplantation.

Design outcomes

Primary

Measure	Time frame
serum interleukin level;	—

Secondary

Measure	Time frame
EBV-DNA;	—

Countries

China

Contacts

Public ContactChen Jiayan

Huadong Hospital

chenjiayan1986@126.com+86 17701863366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026